An announcement was made by the National Vaccination Committee regarding the vaccination with the AstraZeneca vaccine. The announcement emphasizes that it has examined the data available so far and unanimously considers that there is no reason to modify its proposal of 11/3/2021. In other words, the Vaccination Committee emphasizes that vaccinations continue.
The whole announcement of the Vaccination Committee:
The National Vaccination Committee in its meeting today (16-3-2021) re-examined the issue that arose with reports of individual cases of thromboembolic events in people who had been vaccinated with the AstraZeneca vaccine. Despite preventive temporary suspension of vaccinations from additional countries.
The Committee has examined the data available to date and unanimously considers that there is no reason to amend its recommendation of 11/3/2021. The Commission notes that the European Medicines Agency (EMA) and the World Health Organization (WHO), which have access to all data from all countries, recommend that vaccination with the AstraZeneca vaccine be continued.
It is reiterated that the National Vaccination Committee, in collaboration with the AEO Pharmacovigilance Committee, gives absolute priority to vaccine safety issues. Thus, they continuously monitor the evaluations of EMA and WHO. As well as the reports of possible side effects of all vaccines against COVID-19.
In conclusion, the National Vaccination Committee, taking into account all the data, unanimously recommends the continuation of the vaccination. The AstraZeneca vaccine in our country according to the planning that has been done will continue.